Endo Presses On With Generic OxyContin Despite Risks

Law360, New York (February 7, 2006, 12:00 AM EST) -- Endo Pharmaceuticals’ risk-fraught decision to continue marketing its generic version of painkiller OxyContin even after losing a patent challenge at the Federal Circuit shows just how far the generics industry is willing to go in the brutally competitive marketplace, experts say.

Endo vowed this week to continue commercial sales of the drug, a tactic which patent attorneys say is risky, but no longer as uncommon as it used to be.

Last week, in a surprising turnaround, the U.S. Court of Appeals for the Federal Circuit vacated...
To view the full article, register now.